irinotecan has been researched along with Genital Neoplasms, Female in 15 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 8 (53.33) | 18.2507 |
| 2000's | 1 (6.67) | 29.6817 |
| 2010's | 5 (33.33) | 24.3611 |
| 2020's | 1 (6.67) | 2.80 |
| Authors | Studies |
|---|---|
| Gou, R; Horikawa, N; Inayama, Y; Ito, K; Kosaka, K; Nakatani, E; Tani, H; Tsuji, M; Umemiya, M; Yoshida, T; Yu, S | 1 |
| Abu-Rustum, NR; Andikyan, V; Barakat, RR; Chi, DS; Khoury-Collado, F; Konner, JA; O'Cearbhaill, RE; Sandadi, S; Sonoda, Y; Tew, WP | 1 |
| Akahane, T; Aoki, D; Hirasawa, A; Kataoka, F; Kosaki, K; Makita, K; Nomura, H; Okubo, K; Saito, K; Susumu, N; Tanigawara, Y; Tominaga, E; Zama, T | 1 |
| Ariyoshi, Y; Fukuoka, M; Kakihata, K; Masatani, S; Sakata, Y; Shimazaki, M; Shiozawa, T; Tadokoro, J; Yamaguchi, F | 1 |
| Kotsuji, F; Kurokawa, T; Masada, M; Matsunaga, A; Nakamura, T; Sawamura, Y; Shinagawa, A; Tsuyoshi, H; Yano, R; Yoneda, M; Yoshida, Y | 1 |
| Fujiwara, H; Harada, T; Itamochi, H; Kigawa, J; Machida, S; Oishi, T; Sato, S; Shimada, M; Suzuki, M; Takei, Y | 1 |
| Fushiki, H | 1 |
| Rothenberg, ML | 1 |
| Gutzler, F | 1 |
| Sugiyama, T; Ushijima, K; Yakushiji, M | 1 |
| Cottu, PH; Espie, M; Extra, JM; Lerebours, F; Marty, M | 1 |
| Armand, JP; Couteau, C | 1 |
| Itoh, N; Kondoh, H; Mori, H; Tamaya, T | 1 |
| Taguchi, T | 1 |
| Hanabayashi, T; Itoh, N; Kondoh, H; Mori, H; Sawairi, M; Tamaya, T | 1 |
6 review(s) available for irinotecan and Genital Neoplasms, Female
| Article | Year |
|---|---|
[Kampo therapy for side effects of gynecologic carcinomatous chemotherapy].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Cytokines; Drugs, Chinese Herbal; Female; Genital Neoplasms, Female; Hematopoiesis; Humans; Irinotecan; Leukopenia; Lymphocyte Activation; Mice; Nausea; Peripheral Nervous System Diseases; Phytotherapy; Thrombocytopenia; Vomiting; Weight Loss | 2004 |
CPT-11: an original spectrum of clinical activity.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Enzyme Inhibitors; Female; Genital Neoplasms, Female; Humans; Irinotecan; Lung Neoplasms; Neoplasms; Topoisomerase I Inhibitors | 1996 |
[Promising new drugs for gynecological cancer].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Clinical Trials, Phase I as Topic; Cyclophosphamide; Docetaxel; Drug Administration Schedule; Female; Genital Neoplasms, Female; Humans; Irinotecan; Organoplatinum Compounds; Paclitaxel; Taxoids; Topotecan | 1997 |
[Clinical activity spectrum of irinotecan].
Topics: Adenocarcinoma; Adult; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bronchial Neoplasms; Camptothecin; Carcinoma, Small Cell; Child; Clinical Trials as Topic; Digestive System Neoplasms; Disease-Free Survival; Drug Administration Schedule; Enzyme Inhibitors; Female; Genital Neoplasms, Female; Hematologic Neoplasms; Humans; Irinotecan; Male; Neoplasm Proteins; Neoplasms; Remission Induction; Survival Rate; Topoisomerase I Inhibitors; Treatment Outcome | 1998 |
[Irinotecan-containing combinations in solid tumors, except colonic carcinomas].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Diarrhea; Docetaxel; Enzyme Inhibitors; Etoposide; Female; Genital Neoplasms, Female; Humans; Irinotecan; Lung Neoplasms; Lymphoma, Non-Hodgkin; Male; Neoplasm Proteins; Neoplasms; Neutropenia; Paclitaxel; Stomach Neoplasms; Taxoids; Topoisomerase I Inhibitors; Treatment Outcome | 1998 |
[DNA topoisomerase inhibitor as chemotherapeutic drug--clinical point of view].
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Dogs; Drug Evaluation; Female; Genital Neoplasms, Female; Humans; Irinotecan; Leukocyte Count; Lung Neoplasms; Mice; Neoplasms, Experimental; Topoisomerase I Inhibitors | 1991 |
1 trial(s) available for irinotecan and Genital Neoplasms, Female
| Article | Year |
|---|---|
Area under the curve calculation of nedaplatin dose used in combination chemotherapy with irinotecan in a phase I study of gynecologic malignancies.
Topics: Adult; Aged; Anemia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Dose-Response Relationship, Drug; Female; Genetic Variation; Genital Neoplasms, Female; Glucuronosyltransferase; Humans; Irinotecan; Middle Aged; Nausea; Neutropenia; Organoplatinum Compounds | 2012 |
8 other study(ies) available for irinotecan and Genital Neoplasms, Female
| Article | Year |
|---|---|
Risk Factors for Septic Shock After Irinotecan-Containing Chemotherapy: An Exploratory Case-Control Study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Case-Control Studies; Enterocolitis, Neutropenic; Female; Genital Neoplasms, Female; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Retrospective Studies; Risk Factors; Shock, Septic | 2022 |
Feasibility of adjuvant chemotherapy after pelvic exenteration for gynecologic malignancies.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Deoxycytidine; Endometrial Neoplasms; Feasibility Studies; Female; Follow-Up Studies; Gemcitabine; Genital Neoplasms, Female; Humans; Irinotecan; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Pelvic Exenteration; Prognosis; Retrospective Studies; Survival Rate; Topotecan | 2013 |
Polymorphisms in the UGT1A1 gene predict adverse effects of irinotecan in the treatment of gynecologic cancer in Japanese patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Asian People; Camptothecin; Drug-Related Side Effects and Adverse Reactions; Female; Gene Frequency; Genital Neoplasms, Female; Glucuronosyltransferase; Humans; Irinotecan; Middle Aged; Polymorphism, Genetic; Retrospective Studies | 2013 |
Post-marketing surveillance (PMS) of all patients treated with irinotecan in Japan: clinical experience and ADR profile of 13,935 patients.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Colorectal Neoplasms; Diarrhea; Drug Administration Schedule; Female; Genital Neoplasms, Female; Glucuronosyltransferase; Humans; Incidence; Infusions, Intravenous; Irinotecan; Japan; Leukopenia; Lung Neoplasms; Male; Middle Aged; Neoplasms; Patient Selection; Polymorphism, Genetic; Product Surveillance, Postmarketing; Risk Assessment; Risk Factors; Surveys and Questionnaires; Thrombocytopenia | 2011 |
Transient elevation of international normalized ratio during cisplatin-based chemotherapy in patients who are taking warfarin.
Topics: Anticoagulants; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Drug Interactions; Drug Monitoring; Female; Genital Neoplasms, Female; Humans; International Normalized Ratio; Irinotecan; Middle Aged; Thromboembolism; Treatment Outcome; Venous Thrombosis; Warfarin | 2011 |
[New drugs. Topoisomerase inhibitors].
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Female; Genital Neoplasms, Female; Humans; Irinotecan; Structure-Activity Relationship; Topoisomerase I Inhibitors; Topotecan; Treatment Outcome | 1996 |
Treatment of recurrent gynaecologic malignancies with a new camptothecin derivative.
Topics: Adult; Antineoplastic Agents, Phytogenic; Camptothecin; Female; Genital Neoplasms, Female; Humans; Irinotecan; Lung Neoplasms; Middle Aged | 1992 |
Augmentation of antiproliferative activity of CPT-11, a new derivative of camptothecin, by tumor necrosis factor against proliferation of gynecologic tumor cell lines.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Division; Drug Synergism; Female; Genital Neoplasms, Female; Humans; Irinotecan; Recombinant Proteins; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha | 1991 |